Xigris

Active Substance: drotrecogin alfa (activated)
Common Name: drotrecogin alfa (activated)
ATC Code: B01AD10
Marketing Authorisation Holder: Eli Lilly Nederland B.V.
Active Substance: drotrecogin alfa (activated)
Status: Withdrawn
Authorisation Date: 2002-08-22
Therapeutic Area: Sepsis Multiple Organ Failure
Pharmacotherapeutic Group: Antithrombotic agents

Therapeutic Indication

Xigris is indicated for the treatment of adult patients with severe sepsis with multiple organ failure when added to best standard care. The use of Xigris should be considered mainly in situations when therapy can be started within 24 hours after the onset of organ failure (for further information see section 5.1).

The marketing authorisation for Xigris has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web2)